Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?

Diabetes and Metabolism

Volumn 42, Issue 3, 2016, Pages 142-156

  Targher, G ^a   Marchesini, G ^b   Byrne, C D ^c,d  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Diabetes risk; Epidemiology; NAFLD; Non alcoholic fatty liver disease; Type 2 diabetes

Indexed keywords

GLUCAGON; INCRETIN; INSULIN;

BIOLOGICAL ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF CARBOHYDRATE METABOLISM; EPIDEMIOLOGICAL DATA; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIVER DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; REVIEW; RISK FACTOR; WEIGHT REDUCTION; CAUSALITY; COMORBIDITY; COMPLICATION; DIABETES MELLITUS, TYPE 2; NON-ALCOHOLIC FATTY LIVER DISEASE;

CAUSALITY; COMORBIDITY; DIABETES MELLITUS, TYPE 2; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84973667631     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2016.04.002     Document Type: Review

References (91)

1. Rinella M.E. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015, 313:2263-2273.
2. Lonardo A., Bellentani S., Argo C.K., Ballestri S., Byrne C.D., et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis 2015, 47:997-1006. Non-alcoholic Fatty Liver Disease Study Group.
3. Byrne C.D., Targher G. NAFLD: a multisystem disease. J Hepatol 2015, 62:S47-S64.
4. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363:1341-1350.
5. Lonardo A., Ballestri S., Marchesini G., Angulo P., Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 2015, 47:181-190.
6. Fraser A., Harris R., Sattar N., Ebrahim S., Davey Smith G., Lawlor D.A. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009, 32:741-750.
7. Musso G., Gambino R., Cassader M., Pagano G., Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011, 43:617-649.
8. Ballestri S., Zona S., Targher G., Romagnoli D., Baldelli E., Nascimbeni F., et al. Nonalcoholic fatty liver disease is associated with an almost two-fold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 2015, [Epub ahead of print]. 10.1111/jgh.13264.
9. Okamoto M., Takeda Y., Yoda Y., Kobayashi K., Fujino M.A., Yamagata Z. The association of fatty liver and diabetes risk. J Epidemiol 2003, 13:15-21.
10. Fan J.G., Li F., Cai X.B., Peng Y.D., Ao Q.H., Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007, 22:1086-1091.
11. Shibata M., Kihara Y., Taguchi M., Tashiro M., Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007, 30:2940-2944.
12. Kim C.H., Park J.Y., Lee K.U., Kim J.H., Kim H.K. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med 2008, 25:476-481.
13. Yamada T., Fukatsu M., Suzuki S., Wada T., Yoshida T., Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010, 25:352-356.
14. Bae J.C., Rhee E.J., Lee W.Y., Park S.E., Park C.Y., Oh K.W., et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 2011, 34:727-729.
15. Park S.K., Seo M.H., Shin H.C., Ryoo J.H. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 2013, 57:1378-1383.
16. Sung K.C., Jeong W.S., Wild S.H., Byrne C.D. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 2012, 35:717-722.
17. Kasturiratne A., Weerasinghe S., Dassanayake A.S., Rajindrajith S., de Silva A.P., Kato N., et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol 2013, 28:142-147.
18. Chang Y., Jung H.S., Yun K.E., Cho J., Cho Y.K., Ryu S. Cohort study of non-alcoholic fatty liver disease. NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol 2013, 108:1861-1868.
19. Choi J.H., Rhee E.J., Bae J.C., Park S.E., Park C.Y., Cho Y.K., et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res 2013, 44:115-120.
20. Sung K.C., Wild S.H., Byrne C.D. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 2013, 98:3637-3643.
21. Yamazaki H., Tsuboya T., Tsuji K., Dohke M., Maguchi H. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care 2015, 38:1673-1679.
22. Fukuda T., Hamaguchi M., Kojima T., Hashimoto Y., Ohbora A., Kato T., et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int 2016, 36:275-283.
23. Ming J., Xu S., Gao B., Liu G., Ji Y., Yang F., et al. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi'an, China: a five-year cohort study. Liver Int 2015, 35:2401-2407.
24. Li W.D., Fu K.F., Li G.M., Lian Y.S., Ren A.M., Chen Y.J., et al. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus. World J Gastroenterol 2015, 21:9607-9613.
25. Shah R.V., Allison M.A., Lima J.A., Bluemke D.A., Abbasi S.A., Ouyang P., et al. Liver fat, statin use, and incident diabetes: the multi-ethnic study of atherosclerosis. Atherosclerosis 2015, 242:211-217.
26. Ekstedt M., Franzen L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
27. Byrne C.D. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease. Proc Nutr Soc 2013, 72:412-419.
28. Samuel V.T., Shulman G.I. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 2016, 126:12-22.
29. Kantartzis K., Machann J., Schick F., Fritsche A., Haring H.U., Stefan N. The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia 2010, 53:882-889.
30. Gao Z., Zhang J., Kheterpal I., Kennedy N., Davis R.J., Ye J. Sirtuin 1 (SIRT1) protein degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation contributes to hepatic steatosis in obesity. J Biol Chem 2011, 286:22227-22234.
31. Samuel V.T., Liu Z.X., Qu X., Elder B.D., Bilz S., Befroy D., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004, 279:32345-32353.
32. Backhed F., Ding H., Wang T., Hooper L.V., Koh G.Y., Nagy A., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004, 101:15718-15723.
33. Byrne C.D. Dorothy Hodgkin Lecture 2012: Non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med 2012, 29:1098-1107.
34. Mehal W.Z. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev Gastroenterol Hepatol 2013, 10:637-644.
35. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., Lavine J.E., Van Natta M.L., Abdelmalek M.F., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015, 385:956-965.
36. Jornayvaz F.R., Shulman G.I. Diacylglycerol activation of protein kinase Cepsilon and hepatic insulin resistance. Cell Metab 2012, 15:574-584.
37. Cantley J.L., Yoshimura T., Camporez J.P., Zhang D., Jornayvaz F.R., Kumashiro N., et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance. Proc Natl Acad Sci U S A 2013, 110:1869-1874.
38. Samuel V.T., Shulman G.I. Mechanisms for insulin resistance: common threads and missing links. Cell 2012, 148:852-871.
39. Yamaguchi K., Yang L., McCall S., Huang J., Yu X.X., Pandey S.K., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366-1374.
40. Schenk S., Saberi M., Olefsky J.M. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008, 118:2992-3002.
41. Leroux A., Ferrere G., Godie V., Cailleux F., Renoud M.L., Gaudin F., et al. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol 2012, 57:141-149.
42. Perry R.J., Samuel V.T., Petersen K.F., Shulman G.I. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014, 510:84-91.
43. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140:900-917.
44. Tilg H., Moschen A.R. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008, 19:371-379.
45. Watt M.J., Barnett A.C., Bruce C.R., Schenk S., Horowitz J.F., Hoy A.J. Regulation of plasma ceramide levels with fatty acid oversupply: evidence that the liver detects and secretes de novo synthesised ceramide. Diabetologia 2012, 55:2741-2746.
46. Yang G., Badeanlou L., Bielawski J., Roberts A.J., Hannun Y.A., Samad F. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2009, 297:E211-E224.
47. Kolesnick R.N., Kronke M. Regulation of ceramide production and apoptosis. Annu Rev Physiol 1998, 60:643-665.
48. Lipina C., Hundal H.S. Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance. Diabetologia 2011, 54:1596-1607.
49. Luukkonen P.K., Zhou Y., Sadevirta S., Leivonen M., Arola J., Oresic M., et al. Ceramides dissociate steatosis and insulin resistance in the human liver in non-alcoholic fatty liver disease. J Hepatol 2016;64:1167-1175.
50. Bril F., Lomonaco R., Orsak B., Ortiz-Lopez C., Webb A., Tio F., et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology 2014, 59:2178-2187.
51. Pal D., Dasgupta S., Kundu R., Maitra S., Das G., Mukhopadhyay S., et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 2012, 18:1279-1285.
52. Kumar K.G., Trevaskis J.L., Lam D.D., Sutton G.M., Koza R.A., Chouljenko V.N., et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 2008, 8:468-481.
53. Oike Y., Akao M., Kubota Y., Suda T. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. Trends Mol Med 2005, 11:473-479.
54. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005, 115:1627-1635.
55. Misu H., Takamura T., Takayama H., Hayashi H., Matsuzawa-Nagata N., Kurita S., et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab 2010, 12:483-495.
56. Meex R.C., Hoy A.J., Morris A., Brown R.D., Lo J.C., Burke M., et al. Fetuin B is a secreted hepatocyte factor linking steatosis to impaired glucose metabolism. Cell Metab 2015, 22:1078-1089.
57. Baron A.D., Schaeffer L., Shragg P., Kolterman O.G. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1987, 36:274-283.
58. Armstrong M.J., Gaunt P., Aithal G.P., Barton D., Hull D., Parker R., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016, 387:679-690.
59. Ratziu V., Goodman Z., Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol 2015, 62:S65-S75.
60. Mazzella N., Ricciardi L.M., Mazzotti A., Marchesini G. The role of medications for the management of patients with NAFLD. Clin Liver Dis 2014, 18:73-89.
61. Marchesini G., Petta S., Dalle Grave R. Diet, weight loss, and liver health in NAFLD: pathophysiology, evidence and practice. Hepatology 2015, [Epub ahead of print]. 10.1002/hep.28392.
62. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002, 25:2165-2171. The Diabetes Prevention Program Research Group.
63. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
64. Krakoff J., Clark J.M., Crandall J.P., Wilson C., Molitch M.E., Brancati F.L., et al. Effects of metformin and weight loss on serum alanine aminotransferase activity in the Diabetes Prevention Program. Obesity (Silver Spring) 2010, 18:1762-1767.
65. Sun W.H., Song M.Q., Jiang C.Q., Xin Y.N., Ma J.L., Liu Y.X., et al. Lifestyle intervention in non-alcoholic fatty liver disease in Chengyang District, Qingdao, China. World J Hepatol 2012, 4:224-230.
66. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., Torres-Gonzalez A., Gra-Oramas B., Gonzalez-Fabian L., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015, 149:367-378. [e5].
67. Carlsson L.M., Peltonen M., Ahlin S., Anveden A., Bouchard C., Carlsson B., et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012, 367:695-704.
68. Sjoholm K., Sjostrom E., Carlsson L.M., Peltonen M. Weight change-adjusted effects of gastric bypass surgery on glucose metabolism: two- and 10-year results from the Swedish Obese Subjects (SOS) study. Diabetes Care 2015, [pii: dc151407; epub ahead of print].
69. Sjoholm K., Pajunen P., Jacobson P., Karason K., Sjostrom C.D., Torgerson J., et al. Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study. Diabetologia 2015, 58:1448-1453.
70. Burza M.A., Romeo S., Kotronen A., Svensson P.A., Sjoholm K., Torgerson J.S., et al. Long-term effect of bariatric surgery on liver enzymes in the Swedish Obese Subjects (SOS) study. PLoS One 2013, 8:e60495.
71. Lassailly G., Caiazzo R., Buob D., Pigeyre M., Verkindt H., Labreuche J., et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015, 149:379-388.
72. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082-1090.
73. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
74. Ratziu V., Giral P., Jacqueminet S., Charlotte F., Hartemann-Heurtier A., Serfaty L., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008, 135:100-110.
75. Aithal G.P., Thomas J.A., Kaye P.V., Lawson A., Ryder S.D., Spendlove I., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135:1176-1184.
76. Haukeland J.W., Konopski Z., Eggesbo H.B., von Volkmann H.L., Raschpichler G., Bjoro K., et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009, 44:853-860.
77. Shields W.W., Thompson K.E., Grice G.A., Harrison S.A., Coyle W.J. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol 2009, 2:157-163.
78. Ratziu V., Charlotte F., Bernhardt C., Giral P., Halbron M., Lenaour G., et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010, 51:445-453.
79. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675-1685.
80. Lavine J.E., Schwimmer J.B., Van Natta M.L., Molleston J.P., Murray K.F., Rosenthal P., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305:1659-1668.
81. Li Y., Liu L., Wang B., Wang J., Chen D. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep 2013, 1:57-64.
82. Caldwell S.H., Hespenheide E.E., Redick J.A., Iezzoni J.C., Battle E.H., Sheppard B.L. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:519-525.
83. Knowler W.C., Hamman R.F., Edelstein S.L., Barrett-Connor E., Ehrmann D.A., Walker E.A., et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005, 54:1150-1156.
84. DeFronzo R.A., Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 2011, 34(Suppl 2):S202-S209.
85. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M., et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077.
86. Cariou B., Zair Y., Staels B., Bruckert E. Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011, 34:2008-2014.
87. Pedersen J., Holst J.J. Glucagon like-peptide 1 receptor and the liver. Liver Int 2011, 31:1243-1245.
88. Kern M., Kloting N., Niessen H.G., Thomas L., Stiller D., Mark M., et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One 2012, 7:e38744.
89. Kenny P.R., Brady D.E., Torres D.M., Ragozzino L., Chalasani N., Harrison S.A. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol 2010, 105:2707-2709.
90. Armstrong M.J., Hull D., Guo K., Barton D., Hazlehurst J.M., Gathercole L.L., et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 2016, 64:399-408.
91. Gastaldelli A., Marchesini G. Time for glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?. J Hepatol 2016, 64:262-264.